Postby catstaff » Fri Mar 19, 2021 7:28 am
Wonderful news! His case makes me a little more optimistic since it has some similarities to my DH's -- KRAS G12, failed folfox (equivalent). One major difference is that my hubby's primary was far from unknown. But folfiri+bev worked for your DH so I'm hoping it will work for mine.
I noticed that onvansertib came up in this thread earlier. We tried to get DH into that trial but he was rejected due to his progression being a month too long after the end of first-line treatment. Apparently the progression in the primary while on folfox didn't count. They also seemed, shall I put it, unwelcoming of his atypical spread. I found a comment at, of all places a stock-tips site suggesting that the drug is unlikely to be the miracle treatment the company is touting. (For one thing, they don't take into account patients who dropped out of the trial.) PLK1 inhibitors also do not have a good track record so far; one has already failed a Phase III trial. But perhaps we'll have better information fairly soon.
D/H Dx 10/2019 RC age 61
Clinical T4bN2M1a (common iliac and para-aortic lymph nodes)
MSS KRAS G12D
CRT 11/19-1/20 FOLFOX 3/20-7/20
Pelvic exenteration w/LAR 8/20
ypT4bN0Mx G3 0/14 nodes LVI not seen PNI-
CEA 10/19:20, 1/20-11/20:1.6, 4.3, 3.4, 2.7, 2/21:9.0 3/21:18,40 4/21:28,19, 5/21:13.3,8.6
PET 3/21 recurrence in distal nodes, L5 vertebra, pelvis
FOLFIRI+bev 3/21-